SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.

• Tác giả: Vicente Alfaro, Giuseppe Badalamenti, Jean-Yves Blay, Gaston Boggio, Javier Martin Broto, Irene Carrasco, Sant P Chawla, Gregory M Coté, George Demetri, Cristian Fernandez, Robin L Jones, Carmen Kahatt, Bernd Kasper, Axel Le Cesne, Antonio Nieto, Paloma Peinado, Salvatore Tafuto, Mia C Weiss, Joseph Wooley
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Future oncology (London, England) , 2025
• Bộ sưu tập: NCBI
• ID: 54755

Tóm tắt

Previous phase I/II trials indicate promising activity of lurbinectedin plus doxorubicin (DOX) in leiomyosarcoma (LMS). We describe here the rationale and design of SaLuDo, an open label, randomized, multicenter, seamless phase IIb/III study to evaluate the antitumor activity and safety of lurbinectedin plus DOX